Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against Invasive Pneumococcal Disease incidence in European adults aged 65 years and above: results of SpIDnet/I-MOVE+ multicentre study (2012-2016)

Camelia Savulescu, P. Valentiner-Branth, J. Mereckiene, B.A. Winje, P. Ciruela, P. Latasa, M. Guevara, Raymond Bernard Carragher, T. Dalby, M. Corcoran, D.F. Vestrheim, C. Munoz-Almagro, J.C. Sanz, J. Castilla, A. Smith, E. Colzani , L. Pastore-Celentano, G. Hanquet

Research output: Contribution to conferencePoster

Abstract

Background and Aims: We measured the effectiveness of 23-valent pneumococcal polysaccharidic vaccine(PPV23) against invasive pneumococcal disease (IPD) in 65+ year-olds, pooling surveillance data from seven European sites. PPV23 vaccination is recommended in all sites (8-69% uptake) and PCV13 in high risk groups in two sites (<5%uptake). Methods: We compared the vaccination status of IPD cases caused byPPV23 serotypes (cases) to that of nonPPV23 IPD (controls) notified between2012 and 2016. We defined PPV23 vaccination as at least one dose. PPV23 pooled effectiveness was calculated as (1 –odds ratio of vaccination)*100, adjusted for site, age, sex, underlying conditions and year. We stratified PPV23effectiveness by time since last dose of vaccine: <2, 2-4, 5-9 and 10+years. Results: We included 2011 cases and 878 controls. Compared to controls,cases were younger (p=0.001), less likely to have an underlying condition(p=0.025), more likely to be admitted for intensive care (p=0.038) and to have pneumonia (p=0.005). PPV23 effectiveness was 24% (95%CI: 4; 41) against PPV23-serotypes.By serotype, PPV23 effectiveness ranged between -2% (95%CI: -48; 30) against serotype 3 (n=687) and 55% (95%CI: 15; 76) against serotype 9N IPD (n=540). By years since vaccination, PPV23 effectiveness was 43% (95%CI: 3-66) and 15%(95%CI: -25; 43) for <2 years and 10+ years, respectively. Conclusion: Our findings suggest a low PPV23 effectiveness against IPD caused by PPV23serotypes in the elderly, varying by serotype, and higher in the first two years after vaccination. Despite low effectiveness, PPV23 in the elderly may prevent at least 25% of cases among vaccinated.

Conference

Conference11th International Symposium on Pneumococci and Pneumococcal Diseases
Abbreviated titleISPPD
CountryAustralia
CityMelbourne
Period15/04/1819/04/18

Fingerprint

Polysaccharides
Pneumococcal Vaccines
Vaccine
Vaccination
Multicenter Studies
Incidence
Dose
Likely
Pooling
Odds Ratio
Serogroup
Surveillance
Critical Care
Meta-Analysis
Pneumonia
Vaccines

Keywords

  • pneumococcal
  • pneumoniae
  • IPD
  • Vaccine
  • Effectiveness
  • PPV23
  • Elderly

Cite this

Savulescu, C., Valentiner-Branth, P., Mereckiene, J., Winje, B. A., Ciruela, P., Latasa, P., ... Hanquet, G. (2018). Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against Invasive Pneumococcal Disease incidence in European adults aged 65 years and above: results of SpIDnet/I-MOVE+ multicentre study (2012-2016). Poster session presented at 11th International Symposium on Pneumococci and Pneumococcal Diseases, Melbourne, Australia.
Savulescu, Camelia ; Valentiner-Branth, P. ; Mereckiene, J. ; Winje, B.A. ; Ciruela, P. ; Latasa, P. ; Guevara, M. ; Carragher, Raymond Bernard ; Dalby, T. ; Corcoran, M. ; Vestrheim, D.F. ; Munoz-Almagro, C. ; Sanz, J.C. ; Castilla, J. ; Smith, A. ; Colzani , E. ; Pastore-Celentano, L. ; Hanquet, G. / Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against Invasive Pneumococcal Disease incidence in European adults aged 65 years and above : results of SpIDnet/I-MOVE+ multicentre study (2012-2016). Poster session presented at 11th International Symposium on Pneumococci and Pneumococcal Diseases, Melbourne, Australia.1 p.
@conference{9ed3564e550f4698ad9ba4ed6eb4f4ae,
title = "Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against Invasive Pneumococcal Disease incidence in European adults aged 65 years and above: results of SpIDnet/I-MOVE+ multicentre study (2012-2016)",
abstract = "Background and Aims: We measured the effectiveness of 23-valent pneumococcal polysaccharidic vaccine(PPV23) against invasive pneumococcal disease (IPD) in 65+ year-olds, pooling surveillance data from seven European sites. PPV23 vaccination is recommended in all sites (8-69{\%} uptake) and PCV13 in high risk groups in two sites (<5{\%}uptake). Methods: We compared the vaccination status of IPD cases caused byPPV23 serotypes (cases) to that of nonPPV23 IPD (controls) notified between2012 and 2016. We defined PPV23 vaccination as at least one dose. PPV23 pooled effectiveness was calculated as (1 –odds ratio of vaccination)*100, adjusted for site, age, sex, underlying conditions and year. We stratified PPV23effectiveness by time since last dose of vaccine: <2, 2-4, 5-9 and 10+years. Results: We included 2011 cases and 878 controls. Compared to controls,cases were younger (p=0.001), less likely to have an underlying condition(p=0.025), more likely to be admitted for intensive care (p=0.038) and to have pneumonia (p=0.005). PPV23 effectiveness was 24{\%} (95{\%}CI: 4; 41) against PPV23-serotypes.By serotype, PPV23 effectiveness ranged between -2{\%} (95{\%}CI: -48; 30) against serotype 3 (n=687) and 55{\%} (95{\%}CI: 15; 76) against serotype 9N IPD (n=540). By years since vaccination, PPV23 effectiveness was 43{\%} (95{\%}CI: 3-66) and 15{\%}(95{\%}CI: -25; 43) for <2 years and 10+ years, respectively. Conclusion: Our findings suggest a low PPV23 effectiveness against IPD caused by PPV23serotypes in the elderly, varying by serotype, and higher in the first two years after vaccination. Despite low effectiveness, PPV23 in the elderly may prevent at least 25{\%} of cases among vaccinated.",
keywords = "pneumococcal, pneumoniae, IPD, Vaccine, Effectiveness, PPV23, Elderly",
author = "Camelia Savulescu and P. Valentiner-Branth and J. Mereckiene and B.A. Winje and P. Ciruela and P. Latasa and M. Guevara and Carragher, {Raymond Bernard} and T. Dalby and M. Corcoran and D.F. Vestrheim and C. Munoz-Almagro and J.C. Sanz and J. Castilla and A. Smith and E. Colzani and L. Pastore-Celentano and G. Hanquet",
year = "2018",
month = "4",
day = "17",
language = "English",
note = "11th International Symposium on Pneumococci and Pneumococcal Diseases, ISPPD ; Conference date: 15-04-2018 Through 19-04-2018",

}

Savulescu, C, Valentiner-Branth, P, Mereckiene, J, Winje, BA, Ciruela, P, Latasa, P, Guevara, M, Carragher, RB, Dalby, T, Corcoran, M, Vestrheim, DF, Munoz-Almagro, C, Sanz, JC, Castilla, J, Smith, A, Colzani , E, Pastore-Celentano, L & Hanquet, G 2018, 'Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against Invasive Pneumococcal Disease incidence in European adults aged 65 years and above: results of SpIDnet/I-MOVE+ multicentre study (2012-2016)' 11th International Symposium on Pneumococci and Pneumococcal Diseases, Melbourne, Australia, 15/04/18 - 19/04/18, .

Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against Invasive Pneumococcal Disease incidence in European adults aged 65 years and above : results of SpIDnet/I-MOVE+ multicentre study (2012-2016). / Savulescu, Camelia; Valentiner-Branth, P.; Mereckiene, J.; Winje, B.A.; Ciruela, P.; Latasa, P.; Guevara, M.; Carragher, Raymond Bernard; Dalby, T.; Corcoran, M.; Vestrheim, D.F.; Munoz-Almagro, C.; Sanz, J.C.; Castilla, J.; Smith, A.; Colzani , E.; Pastore-Celentano, L.; Hanquet, G.

2018. Poster session presented at 11th International Symposium on Pneumococci and Pneumococcal Diseases, Melbourne, Australia.

Research output: Contribution to conferencePoster

TY - CONF

T1 - Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against Invasive Pneumococcal Disease incidence in European adults aged 65 years and above

T2 - results of SpIDnet/I-MOVE+ multicentre study (2012-2016)

AU - Savulescu, Camelia

AU - Valentiner-Branth, P.

AU - Mereckiene, J.

AU - Winje, B.A.

AU - Ciruela, P.

AU - Latasa, P.

AU - Guevara, M.

AU - Carragher, Raymond Bernard

AU - Dalby, T.

AU - Corcoran, M.

AU - Vestrheim, D.F.

AU - Munoz-Almagro, C.

AU - Sanz, J.C.

AU - Castilla, J.

AU - Smith, A.

AU - Colzani , E.

AU - Pastore-Celentano, L.

AU - Hanquet, G.

PY - 2018/4/17

Y1 - 2018/4/17

N2 - Background and Aims: We measured the effectiveness of 23-valent pneumococcal polysaccharidic vaccine(PPV23) against invasive pneumococcal disease (IPD) in 65+ year-olds, pooling surveillance data from seven European sites. PPV23 vaccination is recommended in all sites (8-69% uptake) and PCV13 in high risk groups in two sites (<5%uptake). Methods: We compared the vaccination status of IPD cases caused byPPV23 serotypes (cases) to that of nonPPV23 IPD (controls) notified between2012 and 2016. We defined PPV23 vaccination as at least one dose. PPV23 pooled effectiveness was calculated as (1 –odds ratio of vaccination)*100, adjusted for site, age, sex, underlying conditions and year. We stratified PPV23effectiveness by time since last dose of vaccine: <2, 2-4, 5-9 and 10+years. Results: We included 2011 cases and 878 controls. Compared to controls,cases were younger (p=0.001), less likely to have an underlying condition(p=0.025), more likely to be admitted for intensive care (p=0.038) and to have pneumonia (p=0.005). PPV23 effectiveness was 24% (95%CI: 4; 41) against PPV23-serotypes.By serotype, PPV23 effectiveness ranged between -2% (95%CI: -48; 30) against serotype 3 (n=687) and 55% (95%CI: 15; 76) against serotype 9N IPD (n=540). By years since vaccination, PPV23 effectiveness was 43% (95%CI: 3-66) and 15%(95%CI: -25; 43) for <2 years and 10+ years, respectively. Conclusion: Our findings suggest a low PPV23 effectiveness against IPD caused by PPV23serotypes in the elderly, varying by serotype, and higher in the first two years after vaccination. Despite low effectiveness, PPV23 in the elderly may prevent at least 25% of cases among vaccinated.

AB - Background and Aims: We measured the effectiveness of 23-valent pneumococcal polysaccharidic vaccine(PPV23) against invasive pneumococcal disease (IPD) in 65+ year-olds, pooling surveillance data from seven European sites. PPV23 vaccination is recommended in all sites (8-69% uptake) and PCV13 in high risk groups in two sites (<5%uptake). Methods: We compared the vaccination status of IPD cases caused byPPV23 serotypes (cases) to that of nonPPV23 IPD (controls) notified between2012 and 2016. We defined PPV23 vaccination as at least one dose. PPV23 pooled effectiveness was calculated as (1 –odds ratio of vaccination)*100, adjusted for site, age, sex, underlying conditions and year. We stratified PPV23effectiveness by time since last dose of vaccine: <2, 2-4, 5-9 and 10+years. Results: We included 2011 cases and 878 controls. Compared to controls,cases were younger (p=0.001), less likely to have an underlying condition(p=0.025), more likely to be admitted for intensive care (p=0.038) and to have pneumonia (p=0.005). PPV23 effectiveness was 24% (95%CI: 4; 41) against PPV23-serotypes.By serotype, PPV23 effectiveness ranged between -2% (95%CI: -48; 30) against serotype 3 (n=687) and 55% (95%CI: 15; 76) against serotype 9N IPD (n=540). By years since vaccination, PPV23 effectiveness was 43% (95%CI: 3-66) and 15%(95%CI: -25; 43) for <2 years and 10+ years, respectively. Conclusion: Our findings suggest a low PPV23 effectiveness against IPD caused by PPV23serotypes in the elderly, varying by serotype, and higher in the first two years after vaccination. Despite low effectiveness, PPV23 in the elderly may prevent at least 25% of cases among vaccinated.

KW - pneumococcal

KW - pneumoniae

KW - IPD

KW - Vaccine

KW - Effectiveness

KW - PPV23

KW - Elderly

UR - https://isppd.kenes.com/2018/Pages/default.aspx

M3 - Poster

ER -

Savulescu C, Valentiner-Branth P, Mereckiene J, Winje BA, Ciruela P, Latasa P et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against Invasive Pneumococcal Disease incidence in European adults aged 65 years and above: results of SpIDnet/I-MOVE+ multicentre study (2012-2016). 2018. Poster session presented at 11th International Symposium on Pneumococci and Pneumococcal Diseases, Melbourne, Australia.